ARTICLE | Management Tracks
Saunders joins BridgeBio’s board; plus changes at BioXcel, FibroGen, Storm, Athenex, Seres, Chimerix and Catalyst
June 26, 2020 1:06 AM UTC
Brent Saunders has joined the the board of BridgeBio Pharma Inc. (NASDAQ:BBIO); he was chairman, president and CEO of Allergan plc in 2015-20 until its takeout by AbbVie Inc. (NYSE:ABBV) in May. The genetic diseases company also named co-founder Andrew Lo and Randy Scott to the board. Scott was executive chairman and CEO of Invitae Corp. (NYSE:NVTA).
BioXcel Therapeutics Inc. (NASDAQ:BTAI), which uses AI to repurpose therapies for neurological diseases and immuno-oncology, hired Reina Benabou as SVP and chief development officer, a new position. She was SVP and CMO of Cognivue Inc., and previously was VP of global medical affairs at Novartis AG (NYSE:NVS; SIX:NOVN) in 2014-16...